UNITED STATES SECURITIES AND EXCHANGE COMMISSION MAY 6, 2015

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES ACT OF 1933

Adaptimmune Therapeutics plc

File No. 333-203267 - CF#32063

Adaptimmune Therapeutics plc submitted an application under Rule 406 requesting confidential treatment for information it excluded from the Exhibits to a Form F-1 registration statement filed on April 6, 2015, as amended.

Based on representations by Adaptimmune Therapeutics plc that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.1	through April 27, 2025
Exhibit 10.2	through April 27, 2025
Exhibit 10.3	through April 27, 2022
Exhibit 10.4	through April 27, 2022
Exhibit 10.11	through April 27, 2025
Exhibit 10.12	through April 27, 2025
Exhibit 10.13	through April 27, 2025

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary